Results 1 to 10 of about 2,981,264 (162)

First-Line Treatment of ALK-Positive NSCLC

healthbook TIMES. Oncology Hematology, 2019
Non-small cell lung cancer (NSCLC) patients with rearrangements in the anaplastic lymphocyte kinase (ALK) gene are highly sensitive to ALK tyrosine kinase inhibitors (TKIs) like alectinib. Here, the case of a 77-year-old male patient with newly diagnosed
Hasna Bouchaab
doaj   +3 more sources

Clinical audit of current Helicobacter pylori treatment outcomes in Singapore

Singapore Medical Journal, 2022
Introduction: H. pylori eradication reduces the risk of gastric malignancies and peptic ulcer disease. First-line therapies include 14-day PAC (proton pump inhibitor [PPI], amoxicillin, clarithromycin) and PBMT (PPI, bismuth, metronidazole, tetracycline).
Tiing Leong Ang, Kim Wei Lim, Daphne Ang, Yu Jun Wong, Malcolm Tan, Andrew Siang Yih Wong   +5 more
doaj   +1 more source

First‐Line Treatment for Hypertension [PDF]

The Journal of Clinical Hypertension, 2011
Expert recommendations have until nowfocused on comparative analyses of cardiovascularoutcomes, efficacy in reducing blood pressure (BP),adverse effects, and cost. Essential hypertension can beclassified into distinct subtypes depending on the pri-mary hemodynamic derangement, which can either beincreased cardiac output (CO), as is more commonlyseen in ...
Stewart Siu-Wa, Chan, Colin A, Graham, Timothy Hudson, Rainer   +2 more
openaire   +2 more sources

Therapeutic Effect of Apatinib in First-line Treatment of Advanced Liver Cancer

Zhongliu Fangzhi Yanjiu, 2021
Objective To explore the effect of apatinib in first-line treatment of advanced liver cancer. Methods Retrospective analysis was performed on 35 patients with advanced liver cancer treated in our department from July 2017 to January 2020.
KE Shaobo, WANG Jing, QIU Hu, CAI Gaoke, GONG Yi, CHEN Yongshun   +5 more
doaj   +1 more source

Treatment patterns for advanced non-small cell lung cancer in the US: A systematic review of observational studies

Cancer Treatment and Research Communications, 2022
Background: The advent of immunotherapies (I-O) and targeted therapies has transformed the treatment landscape in advanced non-small cell lung cancer (NSCLC).
Adam Lee, Yong Yuan, Laura Eccles, Anushri Chitkara, Johan Dalén, Nebibe Varol   +5 more
doaj   +1 more source

Durability of first-line antiretroviral treatment in the Russian Federation: retrospective study

Журнал инфектологии, 2023
Objective. To assess durability of antiretroviral therapy in first line in HIV-infected patients in real clinical practice in the Russian Federation and determine association between basic clinical and demographic characteristics and durability of ...
N. V. Sizova, Yu. K. Plotnikova, T. E. Shimonova, O. E. Chernova, E. S. Ivanova, E. S. Obizhaeva, V. F. Achikyan   +6 more
doaj   +1 more source

Rituximab Therapy for Primary Membranous Nephropathy in a Chinese Cohort

Frontiers in Medicine, 2021
Background: Rituximab has become one of the first-line therapies for the treatment of moderate and high-risk primary membranous nephropathy (pMN).
Shuang Gao, Shuang Gao, Shuang Gao, Shuang Gao, Zhao Cui, Zhao Cui, Zhao Cui, Zhao Cui, Xin Wang, Xin Wang, Xin Wang, Xin Wang, Yi-miao Zhang, Yi-miao Zhang, Yi-miao Zhang, Yi-miao Zhang, Fang Wang, Fang Wang, Fang Wang, Fang Wang, Xu-yang Cheng, Xu-yang Cheng, Xu-yang Cheng, Xu-yang Cheng, Li-qiang Meng, Li-qiang Meng, Li-qiang Meng, Li-qiang Meng, Fu-de Zhou, Fu-de Zhou, Fu-de Zhou, Fu-de Zhou, Gang Liu, Gang Liu, Gang Liu, Gang Liu, Ming-hui Zhao, Ming-hui Zhao, Ming-hui Zhao, Ming-hui Zhao, Ming-hui Zhao   +40 more
doaj   +1 more source

Efficacy and Safety of PD-1/PD-L1 Inhibitors Plus Chemotherapy Versus PD-1/PD-L1 Inhibitors in Advanced Non-Small Cell Lung Cancer: A Network Analysis of Randomized Controlled Trials

Frontiers in Oncology, 2021
Immune checkpoint inhibitors (ICIs) are recommended as first-line treatment for late-stage non-small cell lung cancer (NSCLC), either as monotherapy or in combination with chemotherapy. However, efficacy and safety comparisons between ICIs as monotherapy
Xiang Li, Shi Yan, Jichun Yang, Yaqi Wang, Chao Lv, Shaolei Li, Jun Zhao, Yue Yang, Minglei Zhuo, Nan Wu   +9 more
doaj   +1 more source

Chemotherapy in Pancreatic Cancer: A Systematic Review

Medicina, 2018
Background and Aim: Pancreatic cancer is one of the most fatal cancers. Cytotoxic chemotherapy remains the mainstream treatment for unresectable pancreatic cancer.
Leva Hajatdoost, Keyvan Sedaghat, Erin J. Walker, Jackson Thomas, Sam Kosari   +4 more
doaj   +1 more source

Immunotoxicity of pembrolizumab in patients with metastatic non-small cell lung cancer: A single-centre study [PDF]

Archive of Oncology
Background: Immunotherapy represents a new form of treatment that stimulates the immune system to destroy cancer cells. Pembrolizumab is a humanized monoclonal antibody that binds to the PD-1 programmed cell death receptor and blocks its interaction with
Stojanović Miloš, Bursać Daliborka
doaj   +1 more source